Posted on 03/25/2010 11:26:12 AM PDT by decimon
New research in the FASEB Journal reports that a novel enzyme-linked immunosorbent assay could be a critical diagnostic tool for the detection of A-Beta oligomers, proteins which cause Alzheimer’s disease
A new test developed by Japanese scientists may revolutionize how and when physicians diagnose Alzheimer's disease. According to a research report published online in The FASEB Journal (http://www.fasebj.org), the new test measures proteins in the spinal fluid known to be one of the main causes of brain degeneration and memory impairment in Alzheimer's patients: high molecular weight A-Beta oligomers. This tool, once fully implemented, would allow physicians to diagnose and treat Alzheimer's disease in its early stages, a time when diagnosing the disease is very difficult.
"Alzheimer's disease is a growing problem, due to aging of the population in all developed countries," said Takahiko Tokuda, M.D., Ph.D., a researcher from the Department of Neurology at the Kyoto Prefectural University of Medicine Graduate School of Medical Science in Japan who was involved in the work. "We hope that our new diagnostic test will, in the future, significantly improve the lives of people with Alzheimer's disease, and lead to much better ways of treating this devastating disorder."
Scientists developed a tool (enzyme-linked immunosorbent assay) that specifically measures A-Beta oligomers. They then compared the levels of these protein aggregates in human cerebrospinal fluid samples among three groups of people: 1) patients with diagnosed Alzheimer's disease; 2) patients with mild cognitive impairment who went on to develop Alzheimer's disease; and 3) a control group with no symptoms of Alzheimer's disease. Results showed that the levels of the a fragments being measured directly correlated to the extent of memory impairment, with the highest levels found in those with confirmed Alzheimer's and intermediate levels in those with mild cognitive impairment. This shows that by measuring the levels of A-Beta oligomers in cerebrospinal fluid, physicians may be able to identify Alzheimer's disease before it can be clinically diagnosed using current methods.
"Baby boomers are getting older and Alzheimer's disease will have a tremendous impact on the memory of a generation and the lives of its children," said Gerald Weissmann, M.D., Editor-in-Chief of The FASEB Journal. "This test is not only useful for the early detection of Alzheimer's disease, but promises to be a marker for the efficacy of newer treatments that are already on the drawing board."
###
Receive monthly highlights from The FASEB Journal by e-mail. Sign up at http://www.faseb.org/fjupdate.aspx. The FASEB Journal (http://www.fasebj.org) is published by the Federation of the American Societies for Experimental Biology (FASEB). The journal has been recognized by the Special Libraries Association as one of the top 100 most influential biomedical journals of the past century and is the most cited biology journal worldwide according to the Institute for Scientific Information.
FASEB comprises 23 societies with more than 90,000 members, making it the largest coalition of biomedical research associations in the United States. FASEB enhances the ability of scientists and engineers to improve—through their research—the health, well-being and productivity of all people. FASEB's mission is to advance health and welfare by promoting progress and education in biological and biomedical sciences through service to our member societies and collaborative advocacy.
Ping.
Under Obamacare, it will stop being a growing problem....
Oops! I thought this was an article about Harry Reid.
Disclaimer: Opinions posted on Free Republic are those of the individual posters and do not necessarily represent the opinion of Free Republic or its management. All materials posted herein are protected by copyright law and the exemption for fair use of copyrighted works.